Recent Updates
Recently added Catalysts
OBX Positive Sentiment

Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting

Friday, November 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Obsidian Therapeutics reported positive updated results for amsoki-cel in patients with advanced melanoma resistant to immune-checkpoint inhibitors. The data comes from both a Phase 1 first-in-human study and a Phase 1/2 multicenter study. These findings suggest promising efficacy for this engineered TIL cell therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Updated results show efficacy in advanced melanoma.
  • Positive data from Phase 1 and Phase 1/2 studies.
  • Amsoki-cel demonstrates potential for ICI-resistant patients.

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive updated results in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel (amsoki-ce

Frequently Asked Questions

What is amsoki-cel?

Amsoki-cel is an engineered tumor-infiltrating lymphocyte therapy.

What were the results of the studies?

The studies showed positive efficacy results in advanced melanoma patients.

What types of melanoma does amsoki-cel target?

Amsoki-cel targets advanced melanoma resistant to immune-checkpoint inhibitors.

When will the data be presented?

The updated data will be presented at the SITC 2026 Annual Meeting.

ShareAdd on Google
Tags: OBX Obsidian Therapeutics amsoki-cel advanced melanoma Phase 1 study ICI-resistant
Last updated: Nov 6, 2026

Biotech snapshot

Cash runway
$0M liquidity · $0M/mo burn
Low dilution risk
Lead asset
OBX-115Phase 2
Tumor Skin →